HLA-DRBI*09 is associated with increased incidence of cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation

被引:10
作者
Du, Jinwei [1 ]
Liu, Jing [1 ]
Gu, Jiangying [1 ]
Zhu, Ping [1 ]
机构
[1] Peking Univ, First Hosp, Dept Hematol, Beijing 100034, Peoples R China
关键词
graft-versus-host disease; human leukocyte antigen; cytomegalovirus; hematopoietic stem cell transplantation;
D O I
10.1016/j.bbmt.2007.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytomegalovirus (CMV) infection is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT); however, we have little information on the clinical association of various human leukocyte antigen (HLA) alleles with CMV infection. We reviewed medical records of 60 patients who underwent allo-HSCT. The effect of the 7 most frequent HLA alleles on the incidence of CMV infection and disease was analyzed, including HLA-A*02, A*11, A*24, B*13, B*40(60), DRB1*15, and DRB1*09. All the patients were monitored for CMV infection at least once weekly within 3 months. CMV infection was found in 38 (63.3%) patients on a median of day 36 (range: 16-89). Diagnosis of CMV disease was established in 6 (10.0%) patients, comprising pneumonia (n = 2), enterocolitis (n = 2), and hemorrhagic cystitis (n = 2). CMV disease was successfully treated using ganciclovir or foscarnet combined with immune globulins in 4 patients. The other 2 patients died without improvement of CMV disease. In multivariate analysis, grade II-IV acute graft-versus-host disease (aGVHD), CMV seronegative donors, and HLA-DRB1*09 were associated with increased incidence of CMW infection and disease after allo-HSCT. We suggest that more cautions should be taken to prevent CNIV infection in patients with HLA-DRB1*09 after allo-HSCT. (c) 2007 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:1417 / 1421
页数:5
相关论文
共 25 条
[1]   Serious infections after unrelated donor transplantation in 136 children: Impact of stem cell source [J].
Barker, JN ;
Hough, RE ;
van Burik, JAH ;
DeFor, TE ;
MacMillan, ML ;
O'Brien, MR ;
Wagner, JE .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (05) :362-370
[2]  
BEATTY PG, 1993, BLOOD, V81, P249
[3]   Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity [J].
Boeckh, M ;
Leisenring, W ;
Riddell, SR ;
Bowden, RA ;
Huang, ML ;
Myerson, D ;
Stevens-Ayers, T ;
Flowers, MED ;
Cunningham, T ;
Corey, L .
BLOOD, 2003, 101 (02) :407-414
[4]  
Couriel D, 1996, BONE MARROW TRANSPL, V18, P347
[5]   Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy [J].
Einsele, H ;
Roosnek, E ;
Rufer, N ;
Sinzger, C ;
Riegler, S ;
Löffler, J ;
Grigoleit, U ;
Moris, A ;
Rammensee, HG ;
Kanz, L ;
Kleihauer, A ;
Frank, F ;
Jahn, G ;
Hebart, H .
BLOOD, 2002, 99 (11) :3916-3922
[6]   Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients [J].
Fallen, PR ;
McGreavey, L ;
Madrigal, JA ;
Potter, M ;
Ethell, M ;
Prentice, HG ;
Guimaraes, A ;
Travers, PJ .
BONE MARROW TRANSPLANTATION, 2003, 32 (10) :1001-1014
[7]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[8]   Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection [J].
Gratama, JW ;
van Esser, JWJ ;
Lamers, CHJ ;
Toumay, C ;
Löwenberg, B ;
Bolhuis, RLH ;
Cornelissen, JJ .
BLOOD, 2001, 98 (05) :1358-1364
[9]   Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality [J].
Hebart, H ;
Brugger, W ;
Grigoleit, U ;
Gscheidle, B ;
Loeffler, J ;
Schafer, H ;
Kanz, L ;
Einsele, H ;
Sinzger, C .
BLOOD, 2001, 97 (07) :2183-2185
[10]  
JIA JS, 2006, J EXP HEMATOL, V14, P749